Imagine spending 2 years as a CEO of a company trying to do something in the renewable energy sector and getting nowhere. Then you somehow decide to switch to developing cancer treatments and make $2 million in a couple of weeks.
That’s similar to what has happened with Antonio Tremino, CEO of Immunovative, Inc. (PINK:IMUN). Yesterday IMUN closed up 32.61% at $0.305 per share, making Mr. Tremino’s shares worth $3.8 million; a month ago, they were worth about $1.8 million.
A big part of why IMUN surged is the pump activity around the company. A number of pumpers have been on the stock since July 30.
Compensations have varied between $5 thousand and $85 thousand. Today the pumping efforts are joined by Davind Cohen’s RDI. A third party has paid $30 thousand for that particular promotion.
RDI is up to its usual touting techniques, trying to convince traders that “missing out could be very painful.” Then again, following RDI’s picks can be painful too. A recent example of RDI’s wonderful work is the double whammy on LDSI previously covered on 
hotstocked. TRON was an older RDI pick.
Some of the traders may have seen the announcement that Goldman Small Cap Research issued a research report on IMUN on Aug. 3. The report gives IMUN a target price of $1.70. Before anyone decides the report is something one can rely on, they had better take a look at what happened with CTDT.
Goldman called CTDT “an Investor’s Best Friend” and gave it a price target of $1.20 on July 16. Less than a month later CTDT is down more than 90%.
Another reason for yesterday’s surge could be the announcement of a $5 million private placement. This may be viewed as good news, but traders should keep in mind that IMUN is committed to secure at least $10 million to support a trial.[BANNER]
Even if everything goes perfectly for IMUN, shareholders won’t get anything any time soon, and at $0.305 the market cap of IMUN is already $41 million. Additionally, it’s not clear when, or even if, the company will start generating revenue, and in the meantime it will have to use equity financing which will further dilute shareholders.
There is a theoretical chance that one day IMUN will do what it has set out to do, but right now traders should do their due diligence and decide whether IMUN is worth $41 million.
With all the pump efforts and hype, Mr. Tremino’s $3.8 million on paper may very easily go back to $1.8 million or less. If the company has nothing to do with the pump campaigns, the management may want to address the situation, in order to protect the interest of its shareholders. Then again, pumps are very often paid by shareholders who want to dump their shares, so the situation may be complicated.
